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Carbon monoxide (CO) poisoning is a leading cause of intentional and unintentional poisoning worldwide, associated with
mortality and severe morbidity. Some survivors of CO poisoning develop, after a lucid interval, a potentially permanent
encephalopathy in the form of cognitive impairment and movement disorders, such as Parkinsonism. One of the most frequent
neuroimaging findings is a cerebral white matter damage, but so far its precise cause and specific therapy are still debated.
We here report the case of a 33-year-old woman with severe carbon monoxide poisoning who, after a period of lucid interval,
presented symptoms of declining motor and cognitive functions. She was treated with 40 sessions of Hyperbaric Oxygen Therapy
(HBOT). The therapeutic use of oxygen at supraphysiological pressures might either increase systemic oxidative stress or cause an
overproduction of oxygen free radicals as drawbacks. Concurrent use of antioxidants and anti-inflammatory drugs may prevent
the side effects of oxygen therapy at supraphysiological pressure due to oxidative stress. For this reason, the patient was also treated
with high-dose N-Acetylcysteine and glucocorticoids. Here, we describe the longitudinal monitoring of patient’s cognitive abilities
and leukoencephalopathy associated with her positive clinical outcome.
1. Introduction
At present, carbon monoxide (CO) poisoning remains a
leading cause of unintentional poisoning worldwide [1]. In
Italy, the estimated incidence is about 6.000 cases per year,
resulting in more than 350 deaths per year [2]. The clinical
symptoms range from headache and confusion to coma and
death, with mortality rates reaching up to 3%.
CO is a nonirritant gas generated during the incom-
plete combustion of carbon-based compounds. Upon expo-
sure, CO binds to hemoglobin with an affinity known
to be 200-300 times greater than oxygen, generating car-
boxyhemoglobin (HbCO). It decreases both the oxygen-
carrying and oxygen-delivery capacity of blood, inducing
tissue hypoxia (HbCO theory) [3]. While the hypoxemic
hypoxia suggested by the HbCO theory is undoubtedly a
key component of CO poisoning mechanisms, it is not
enough to account for some of the neuropathological man-
ifestations of CO poisoning. In recent years, researchers
have demonstrated CO interaction with soluble guanylate
cyclase, ion channels, nitric oxide, nitric oxide synthase,
mitochondria, cytochromes, NAPDH oxidase, and xanthine
oxidase. Direct effects of CO poisoning on separate organ
systems are well explained by these extra-hemoglobin effects,
with the most important being the effects upon nitric
oxide and on reactive oxygen species (ROS). In addition, a
direct effect on cardiac ion channels has been established
[4].
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A significant number of patients who survive CO poi-
soning suffer from delayed neurological sequelae (DNS) that
typically develop between 27 and 270 days after injury. The
DNS reported incidence varies widely from 3 to 40%, because
of the lack of established diagnostic criteria. In the classic
biphasic presentation, patients recovering from acute CO
poisoning manifest a relapse of neurological deficits after a
lucid period, including seizures, consciousness disturbances,
psychiatric disturbances, movement disorders, and urinary
incontinence [5].
The pathophysiology of DNS is not completely under-
stood, though some authors suggested that the typical white
matter involvement in CO poisoning reflects a transient
intramyelinic edema or inflammation, due to brain lipid
peroxidation [6, 7]. Biochemical and immunological studies
found that myelin basic protein (MBP) undergoes anti-
genic alterations after CO-exposure, which suggest that
delayed CO-mediated neuropathology is linked to an adap-
tive immunological response to chemically modified MBP
[8]. In the setting of acute CO poisoning, the standard of
care is high-flow oxygen, preferentially hyperbaric therapy,
and general supportive care [9]. As compared to Normo-
baric Oxygen Therapy (NBOT), Hyperbaric Oxygen Ther-
apy (HBOT) provides increased dissolved-oxygen content
in blood and accelerated elimination of CO. Nonetheless,
existing randomized trials do not establish whether the
administration of HBOT to patients with CO poisoning
reduces the incidence of adverse neurologic outcomes [10].
Currently, in the subacute phase of CO poisoning and/or
DNS, there is no standard treatment and clinical case reports
do not agree about treatment strategies (e.g., the choice
between NBOT and HBOT, the number of sessions) [11–15].
Here, we describe the case of a 33-year-old woman who
suffered from CO acute intoxication and was diagnosed
with DNS after a period of full recovery (i.e., lucid period).
Hyperbaric Oxygen Therapy associated with administration
of ROS scavenger was tentatively performed and the positive
clinical evolution of the patient was monitored through
extensive cognitive testing and radiological assessment.
2. Case Presentation
A previously healthy 33-year-old woman was found uncon-
scious at her house. She was exposed to CO from a faulty
heater and the exposure time was unknown. She was last
heard by her relatives 10 hours earlier, when she referred
experiencing nausea, vomiting, and headache.
She was admitted to intensive care unit (ICU) with a
Glasgow Coma Scale score of 9/15 (E4-M3-V2). Arterial
blood gas sample analysis revealedmetabolic acidosis and her
HbCO level was 20.4 percent. Serum biochemistry disclosed
elevated serum creatinine (1.33 mg/dL) and HS-Troponin T
(188 ng/L). Due to her severe neurological symptoms, she
was intubated and sedated with propofol. No evidence for
alterations of brain tissue was found from either computed
tomography (CT) or magnetic resonance imaging (MRI) at
this point. HBOT (Drass Galeazzi Underwater Technology,
Livorno, Italy) was performed immediately and 24 hours after
admission (80minutes’ exposure at 2.5 atmospheres absolute,
ATA). After 9 days, the patient showed some spontaneous
movement. She gradually regained consciousness and both
cardiac and kidney functions improved.
On the 15th day after her ICU admission, she started
following commands and was subsequently weaned from the
ventilator. She was discharged from the ICU and directed
to the rehabilitation unit on the 18th day after admission.
At first, the patient showed good adherence to rehabilitation
program.
Disability Rating Scale (DRS) [16] measured at this time
revealed a score of 8/30, corresponding to moderately severe
disability.
However, approximately 40 days after the exposure toCO,
she was confused and suffered from slowing of psychomo-
tor functions, impaired short-term memory, and reduced
sustained attention. She was no more able to maintain the
upright position. The symptoms gradually worsened in few
days and she was transferred to our hospital. The patient was
hypomimic and presented stereotypedmovements, especially
with her hands, when she was admitted to the facility. She
was not oriented in time and space, had reduced ability to
sustain attention, and had optic apraxia as well. Her speech
was restricted to short phrases in response to specific requests
and she had anterograde memory deficits. She demonstrated
very poor awareness of her cognitive deficits. The overall
raw score to the Mini-Mental State Examination (MMSE)
[17] was 6/30. DRS at this time reached the score of 16/30,
corresponding to severe disability.
Motor system examination revealed rigid tetraparesis.
Therewas significant truncal and nuchal extensor hypertonia.
She had urinary and bowel incontinence. Examination of the
other systems was normal.
Brain MRI performed on day 45 after exposition showed
confluent bilateral and symmetric white matter hyperin-
tense areas on T2 and Fluid Attenuated Inversion Recovery
(FLAIR) sequences (Figure 2).Thehematologic, biochemical,
and serological studies as well as HbCO levels were unre-
markable. Electroencephalogram showed diffuse slow brain
activity. Based on the clinical history and laboratory/imaging
findings, the diagnosis of DNS was assumed.
Inpatient rehabilitation program consisted of 2 up to 3
hours of physical and speech therapy per weekday. Thera-
peutic rehabilitation techniques focused on obtaining a good
trunk control in sitting position, readjustment to upright
position, muscle strengthening for upper and lower limbs,
initiation of gait training, and improvement of orientation
and attention.
Rehabilitative treatment was performed concurrently
with HBOT and ROS scavenger administration.
HBOT consisted of 40 sessions (two 35 minutes’ oxygen
breathing cycles with air breathing interval for 5 minutes at
2.5 ATA) with the following sequence: once a day for 20 days,
no treatment for 15 days, once a day for 10 days, no treatment
for 15 days, and lastly once a day for 10 days again.
ROS scavenger therapy consisted in intravenous high
dose N-Acetylcysteine (12 g/die in continuous infusion) and
low dosage of oral glucocorticoids (prednisone 25 mg/die).
Since the third session of HBOT, there was a significant
improvement in her motor and cognitive skills: the patient
Case Reports in Neurological Medicine 3
Table 1: Neuropsychological profile at different times after exposition.
Time after exposition (days) 30 45 100 540 Cut-off
Digit span Test 6 4 4 6 ≥ 5
Immediate recall short story 12 1 16 16 ≥ 8
Delayed recall short story 13 3 15 15 ≥ 11
Brown-Peterson Interference Test after 10” 3 0 6 6 ≥ 6
Brown-Peterson Interference Test after 30” 2 0 6 6 ≥ 5
Trail making test -A 91 N. E. 97” 33” ≤ 45”
Trail making test - B N.E. N. E. 342” 107” ≤ 140”
Word fluency Phonemic 3 0 7 26 ≥ 11
Verbal Abstraction Test 6 4 6 6 ≥ 4
Superimposed Silhouettes Test 20 0 31 38 ≥ 35
Drawing copy 1 0 1 2 ≥ 2
Clock drawing test 0 0 0 9 ≥ 8
Praxia Test 5 4 5 6 ≥ 6
Token Test 5 5 5 5 ≥ 5
Cognitive estimation task 5 1 5 5 ≥ 4
Cognitive Quotient 18/30 26/30 16/30 0/30
N.E. indicates that patient was not able to execute the test.
Bolded scores indicate a test under the normal performance range.
Cognitive Quotient: ratio between the number of tests under the normal performance range and the maximum obtainable score (two points for each).
became able to stand in upright position with arms on a
surface. Her sustained attention began to last much longer
and she became oriented in space and time. Language skills
improved in both verbal comprehension and production.
After 100 days and 20 sessions of HBOT, she was
able to walk for approximately 100 meters using a walker-
rollator, however with some gait difficulties. MMSE raw score
improved and reached the cut-off level for absence of cog-
nitive impairment (24/30). Despite these improvements, the
concurrent analytical neuropsychological evaluation showed
performance deficits in several cognitive functions. For this
reason, treatment was continued with 20 more sessions of
HBOT, rehabilitation, and pharmacological therapy.
The neurological profile gradually improved until the
time of discharge (i.e., at the end of the 40 HBOT sessions),
when the patient appeared calm, lucid, and oriented and
was able to relate to others. Complete motor recovery was
observed within 150 days. DRS reached a score of 3/30,
disclosing a partial residual disability.
At 18 months of follow-up, neuropsychological tests were
all within normal range (see Table 1). The patient was now
independent in her activities of daily living and was able to
return to her previous job.
Figure 1 recapitulates the timeline of patient’s clinical
evolution.
The neuropsychological evaluation was carried out in
multiple sessions, each lasting approximately 1 hour. The
patient was sitting and relaxing in a room at a comfortable
temperature and was required to perform tests included in
the battery named “Esame Neuropsicologico Breve” [18],
including a readapted version of the digit span test, trail-
making test, word phonemic fluency, immediate and delayed
recall of a short story, Brown-Peterson Interference Test,
clock drawing test, verbal abstraction test, and Praxia test. To
visually synthesize the cognitive skills’ follow-up,we created a
cognitive quotient (CQ) represented by the ratio between the
number of tests under the normal performance range and the
maximum obtainable score (two points for each).
MRI scans were performed on the 2nd, 30th, 45th, 60th,
150
th, 180th, and 540th days after exposition. MRI images
underwent a specific processing pipeline, aimed at improving
the inspection and qualitative comparison of patient leukoen-
cephalopathy across time-points. In brief, FLAIR imageswere
first brain-extracted using the FSL brain extraction tool [19].
Afterwards, images were linearly transformed (FSL-flirt; 12
DOF affine registration [20]) tomatch a high-resolutionMNI
FLAIR template available at http://brainder.org, using sinc
as interpolation method and a final resolution of 1x1x8mm
(Hanning window, 7 voxels window width). Finally, to
further reduce differences in intensity and contrast among
different time-points, preprocessed images were imported
in MATLAB v8.5.0, adjusted (imadjust) and filtered using
Contrast-limited Adaptive Histogram Equalization algo-
rithm (adapthisteq).The results of this processing pipeline are
presented in Figure 2.
3. Discussion
We report the successful treatment of a 33-year-old woman
suffering from DNS after accidental CO poisoning. Our
patient showed a progressive and sustained clinical improve-
ment in motor, cognitive, and behavioral symptoms, accom-
panied by a reduction on the extent of the white matter
abnormalities in the follow-up MRI study.
To our knowledge, there are no reported cases of patients
with DNS treated with HBOTand concurrent ROS scavenger



















Figure 1: Timeline of clinical course. CO: carbon monoxide. HBOT: Hyperbaric Oxygen Therapy. DRS: Disability Rating Scale (Rappaport
et al., 1992). CQ: cognitive quotient. Corresponding MRI scans are indicated as circles in the clinical course.
therapy. Moreover, our patient was periodically monitored
with a comprehensive battery of neuropsychological tests
aimed at characterizing her cognitive functions in detail.
Chang et al. [21] used MMSE as an outcome measure
after CO poisoning and found a normalization of MMSE
scores after the HBOT. In our patient, the normalization of
MMSE score long predates the complete resolution of neu-
ropsychological deficits in the different cognitive domains.
This suggests the importance of using a battery of neuropsy-
chological tests for the evaluation and follow-up after CO
poisoning. There is still limited evidence on the efficacy of
HBOT in the subacute phase of CO intoxication and/or DNS.
HBOT has complex effects on immunity, oxygen transport,
and hemodynamics. Mechanisms of neuroplasticity and cel-
lular repair by HBOT have been suggested in many animal
studies [22].The ability of HBOT to induce angiogenesis was
demonstrated in several different preclinical studies [23, 24].
HBOTmay also promote neurogenesis of endogenous neural
stem cells [25]. Efrati et al. [26] proved that HBOT can lead to
significant neurological improvements in poststroke patients
even at chronic late stages, implying that neuroplasticity can
still be activated long after damage onset.
Furthermore, HBOThas been proposed for the treatment
of some autoimmune diseases, given its immunosuppressive
effect. HBOT produces changes in lymphocyte redistribu-
tion, suppression of antibody production, and suppression of
leukocyte and macrophage function [27, 28]. Given the role
of adaptive immunological response to chemically modified
myelinic basic protein, HBOT could provide some beneficial
effects in the treatment of CO-poisoned patients. Thom
[29] reported reduced lipid peroxidation with HBOT in rats
with CO poisoning. On the other hand, the therapeutic
use of oxygen, particularly at supraphysiological pressures,
might either increase systemic oxidative stress or cause an
overproduction of oxygen free radicals [30]. An imbalance
of free radical production has been known to result in
deleterious modification of biological macromolecules [31].
ROS are known to mediate O2 toxicity, which for HBOT
includes pulmonary injuries and central nervous system
effects [32]. In addition, ROS formation may promote the
inflammation via endothelial cells, chemotactic signals, and
the release of products from the arachidonic acid cascade. In
central nervous system, this results in progression of demyeli-
nating lesions [33]. As consequence, the concurrent use of
antioxidants and anti-inflammatory drugs may prevent the
side effects of oxygen therapy at supraphysiological pressure
due to oxidative stress. In this case, we administered lowdoses
of glucocorticoids and high doses ofN-Acetylcysteine (NAC).
NAC is an antioxidant, used clinically to protect the liver from
toxic effects of acetaminophen overdose and as mucolytic
drugs. Moreover, in fibrosing alveolitis NAC prevent oxida-
tive damage [34].The effects of NAC are antioxidant because
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Figure 2: Comparison of MRI scans across different time-points after exposition. 30 and 45 days after initial event, FLAIR sequences show a
diffuse and confluent hyperintensity involving predominantly the periventricular and deep white matter. Follow-up MRI scans (60, 150, 180,
and 540 days after initial event) show gradual regression of the FLAIR hyperintensity.
it acts as a source of cysteine for the synthesis of glu-
tathione [35]. NAC has also weak anti-inflammatory effects,
by reducing Nuclear Factor-kB activation [36]. This same
mechanism is responsible for powerful anti-inflammatory
properties of glucocorticoids [37]. In a clinical study, Xiang
[38] reported that the combined application of dexametha-
sone and HBOT, compared with HBOT alone, resulted in
better functional recovery from DNS as assessed by means
ofMMSE score and National Institutes of Health Stroke Scale
(NIHSS) [39] score.Therefore,NACand glucocorticoids have
synergic effects to counteract the supposed physiopathology
of DNS and the putative HBOT-induced oxidative stress.
Although spontaneous recovery cannot be excluded, our
case suggests that a combination of HBOT and antiox-
idant and anti-inflammatory drugs may produce a posi-
tive synergistic effect, which could not be achieved when
these therapies are applied independently. Further research
is needed to clarify the role of antioxidants in the treat-
ment and the time of complete recovery of DNS after CO
poisoning.
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